MedicalHealthcareJobs.com

How personal loss and hope drove Elaine Maynardâ€™s work in clinical trials and patient-centric technologies

Highlights

array(40) {
  [0]=>
  string(4) "9168"
  ["article_id"]=>
  string(4) "9168"
  [1]=>
  string(71) "FDA grants two designations for GenFleetâ€™s drug candidate SLS009"
  ["article_title"]=>
  string(71) "FDA grants two designations for GenFleetâ€™s drug candidate SLS009"
  [2]=>
  string(150) "The fast track and orphan drug designations have been awarded for GFH009 (highly selective CDK9 inhibitor) to treat adult patients with relapsed/refra"
  ["short_description"]=>
  string(150) "The fast track and orphan drug designations have been awarded for GFH009 (highly selective CDK9 inhibitor) to treat adult patients with relapsed/refra"
  [3]=>
  string(570) "The fast track and orphan drug designations have been awarded for GFH009 (highly selective CDK9 inhibitor) to treat adult patients with relapsed/refractory (r/r) peripheral T-cell lymphomas (PTCL) and 
&#nlThe post FDA grants two designations for GenFleet’s drug candidate SLS009 appeared first on Pharmaceutical Business review.&#nl"
  ["description"]=>
  string(570) "The fast track and orphan drug designations have been awarded for GFH009 (highly selective CDK9 inhibitor) to treat adult patients with relapsed/refractory (r/r) peripheral T-cell lymphomas (PTCL) and 
&#nlThe post FDA grants two designations for GenFleet’s drug candidate SLS009 appeared first on Pharmaceutical Business review.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/fda-genfleet-drug-candidate/"
  ["blog_url"]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/fda-genfleet-drug-candidate/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:32"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA grants two designations for GenFleetâ€™s drug candidate SLS009

The fast track and orphan drug designations have been awarded for GFH009 (highly selective CDK9 inhibitor) to treat a

array(40) {
  [0]=>
  string(4) "9169"
  ["article_id"]=>
  string(4) "9169"
  [1]=>
  string(69) "Fermion receives IND approval in China for pain relief drug FZ008-145"
  ["article_title"]=>
  string(69) "Fermion receives IND approval in China for pain relief drug FZ008-145"
  [2]=>
  string(150) "A selective second-generation Nav1.8 inhibitor, FZ008-145 is designed to provide non-addictive pain relief. This Nav1.8 target has been clinically val"
  ["short_description"]=>
  string(150) "A selective second-generation Nav1.8 inhibitor, FZ008-145 is designed to provide non-addictive pain relief. This Nav1.8 target has been clinically val"
  [3]=>
  string(581) "A selective second-generation Nav1.8 inhibitor, FZ008-145 is designed to provide non-addictive pain relief. This Nav1.8 target has been clinically validated in five acute pain and one chronic pain 
&#nlThe post Fermion receives IND approval in China for pain relief drug FZ008-145 appeared first on Pharmaceutical Business review.&#nl"
  ["description"]=>
  string(581) "A selective second-generation Nav1.8 inhibitor, FZ008-145 is designed to provide non-addictive pain relief. This Nav1.8 target has been clinically validated in five acute pain and one chronic pain 
&#nlThe post Fermion receives IND approval in China for pain relief drug FZ008-145 appeared first on Pharmaceutical Business review.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(96) "https://www.pharmaceutical-business-review.com/news/fermion-ind-approval-china-pain-relief-drug/"
  ["blog_url"]=>
  string(96) "https://www.pharmaceutical-business-review.com/news/fermion-ind-approval-china-pain-relief-drug/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:32"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Fermion receives IND approval in China for pain relief drug FZ008-145

A selective second-generation Nav1.8 inhibitor, FZ008-145 is designed to provide non-addictive pain relief. This Nav1

array(40) {
  [0]=>
  string(4) "9170"
  ["article_id"]=>
  string(4) "9170"
  [1]=>
  string(66) "AbbVie introduces Produodopa for advanced Parkinsonâ€™s in EU"
  ["article_title"]=>
  string(66) "AbbVie introduces Produodopa for advanced Parkinsonâ€™s in EU"
  [2]=>
  string(150) "The treatment is indicated for use in PD patients experiencing severe motor fluctuations and hyperkinesia or dyskinesia. This marks the introduction o"
  ["short_description"]=>
  string(150) "The treatment is indicated for use in PD patients experiencing severe motor fluctuations and hyperkinesia or dyskinesia. This marks the introduction o"
  [3]=>
  string(572) "The treatment is indicated for use in PD patients experiencing severe motor fluctuations and hyperkinesia or dyskinesia. This marks the introduction of the first 24-hour continuous subcutaneous infusion 
&#nlThe post AbbVie introduces Produodopa for advanced Parkinsonâ€™s in EU appeared first on Pharmaceutical Business review.&#nl"
  ["description"]=>
  string(572) "The treatment is indicated for use in PD patients experiencing severe motor fluctuations and hyperkinesia or dyskinesia. This marks the introduction of the first 24-hour continuous subcutaneous infusion 
&#nlThe post AbbVie introduces Produodopa for advanced Parkinsonâ€™s in EU appeared first on Pharmaceutical Business review.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(84) "https://www.pharmaceutical-business-review.com/news/abbvie-introduces-produodopa-eu/"
  ["blog_url"]=>
  string(84) "https://www.pharmaceutical-business-review.com/news/abbvie-introduces-produodopa-eu/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:32"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

AbbVie introduces Produodopa for advanced Parkinsonâ€™s in EU

The treatment is indicated for use in PD patients experiencing severe motor fluctuations and hyperkinesia or dyskines

array(40) {
  [0]=>
  string(4) "9371"
  ["article_id"]=>
  string(4) "9371"
  [1]=>
  string(73) "FDA grants orphan drug status to Ractigenâ€™s RAG-18 for DMD and BMD"
  ["article_title"]=>
  string(73) "FDA grants orphan drug status to Ractigenâ€™s RAG-18 for DMD and BMD"
  [2]=>
  string(155) "RAG-18 is claimed to be the first saRNA therapeutic to receive ODD status. DMD and BMD Â are caused by mutations in the DMD gene. The FDA grants ODD &#nl"
  ["short_description"]=>
  string(155) "RAG-18 is claimed to be the first saRNA therapeutic to receive ODD status. DMD and BMD Â are caused by mutations in the DMD gene. The FDA grants ODD &#nl"
  [3]=>
  string(515) "RAG-18 is claimed to be the first saRNA therapeutic to receive ODD status. DMD and BMD Â are caused by mutations in the DMD gene. The FDA grants ODD 
&#nlThe post FDA grants orphan drug status to Ractigenâ€™s RAG-18 for DMD and BMD appeared first on Pharmaceutical Business review.&#nl"
  ["description"]=>
  string(515) "RAG-18 is claimed to be the first saRNA therapeutic to receive ODD status. DMD and BMD Â are caused by mutations in the DMD gene. The FDA grants ODD 
&#nlThe post FDA grants orphan drug status to Ractigenâ€™s RAG-18 for DMD and BMD appeared first on Pharmaceutical Business review.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(72) "https://www.pharmaceutical-business-review.com/news/fda-ractigen-rag-18/"
  ["blog_url"]=>
  string(72) "https://www.pharmaceutical-business-review.com/news/fda-ractigen-rag-18/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:24"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA grants orphan drug status to Ractigenâ€™s RAG-18 for DMD and BMD

RAG-18 is claimed to be the first saRNA therapeutic to receive ODD status. DMD and BMD Â are caused by mutations in

array(40) {
  [0]=>
  string(4) "9372"
  ["article_id"]=>
  string(4) "9372"
  [1]=>
  string(60) "RedHill launches Talicia in UAE to treat H. pylori infection"
  ["article_title"]=>
  string(60) "RedHill launches Talicia in UAE to treat H. pylori infection"
  [2]=>
  string(150) "The launch may lead to additional milestone payments, minimum sales payments, and royalties for RedHill on net sales. Talicia is the only low-dose rif"
  ["short_description"]=>
  string(150) "The launch may lead to additional milestone payments, minimum sales payments, and royalties for RedHill on net sales. Talicia is the only low-dose rif"
  [3]=>
  string(552) "The launch may lead to additional milestone payments, minimum sales payments, and royalties for RedHill on net sales. Talicia is the only low-dose rifabutin-based therapy which received approval 
&#nlThe post RedHill launches Talicia in UAE to treat H. pylori infection appeared first on Pharmaceutical Business review.&#nl"
  ["description"]=>
  string(552) "The launch may lead to additional milestone payments, minimum sales payments, and royalties for RedHill on net sales. Talicia is the only low-dose rifabutin-based therapy which received approval 
&#nlThe post RedHill launches Talicia in UAE to treat H. pylori infection appeared first on Pharmaceutical Business review.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(78) "https://www.pharmaceutical-business-review.com/news/redhill-talicia-infection/"
  ["blog_url"]=>
  string(78) "https://www.pharmaceutical-business-review.com/news/redhill-talicia-infection/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:24"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

RedHill launches Talicia in UAE to treat H. pylori infection

The launch may lead to additional milestone payments, minimum sales payments, and royalties for RedHill on net sales.

array(40) {
  [0]=>
  string(4) "9373"
  ["article_id"]=>
  string(4) "9373"
  [1]=>
  string(72) "GSKâ€™s B7-H3-targeted ADC receives FDA breakthrough therapy status"
  ["article_title"]=>
  string(72) "GSKâ€™s B7-H3-targeted ADC receives FDA breakthrough therapy status"
  [2]=>
  string(150) "This asset is being assessed to treat patients with relapsed or refractory extensive-stage small-cell lung cancer (ES-SCLC) who have shown disease pro"
  ["short_description"]=>
  string(150) "This asset is being assessed to treat patients with relapsed or refractory extensive-stage small-cell lung cancer (ES-SCLC) who have shown disease pro"
  [3]=>
  string(583) "This asset is being assessed to treat patients with relapsed or refractory extensive-stage small-cell lung cancer (ES-SCLC) who have shown disease progression on or following treatment with platinum-based 
&#nlThe post GSK’s B7-H3-targeted ADC receives FDA breakthrough therapy status appeared first on Pharmaceutical Business review.&#nl"
  ["description"]=>
  string(583) "This asset is being assessed to treat patients with relapsed or refractory extensive-stage small-cell lung cancer (ES-SCLC) who have shown disease progression on or following treatment with platinum-based 
&#nlThe post GSK’s B7-H3-targeted ADC receives FDA breakthrough therapy status appeared first on Pharmaceutical Business review.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(88) "https://www.pharmaceutical-business-review.com/news/gsk-fda-breakthrough-therapy-status/"
  ["blog_url"]=>
  string(88) "https://www.pharmaceutical-business-review.com/news/gsk-fda-breakthrough-therapy-status/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:24"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

GSKâ€™s B7-H3-targeted ADC receives FDA breakthrough therapy status

This asset is being assessed to treat patients with relapsed or refractory extensive-stage small-cell lung cancer (ES

array(40) {
  [0]=>
  string(4) "9374"
  ["article_id"]=>
  string(4) "9374"
  [1]=>
  string(92) "FDA grants Fast Track Designation to Arthrosi Therapeuticsâ€™s AR882 for gout treatment"
  ["article_title"]=>
  string(92) "FDA grants Fast Track Designation to Arthrosi Therapeuticsâ€™s AR882 for gout treatment"
  [2]=>
  string(150) "This designation is a critical step in accelerating the drug’s development and review process, recognising the urgent need for new treatments in"
  ["short_description"]=>
  string(150) "This designation is a critical step in accelerating the drug’s development and review process, recognising the urgent need for new treatments in"
  [3]=>
  string(616) "This designation is a critical step in accelerating the drug’s development and review process, recognising the urgent need for new treatments in this area. Arthrosi Therapeutics founder and 
&#nlThe post FDA grants Fast Track Designation to Arthrosi Therapeuticsâ€™s AR882 for gout treatment appeared first on Pharmaceutical Business review.&#nl"
  ["description"]=>
  string(616) "This designation is a critical step in accelerating the drug’s development and review process, recognising the urgent need for new treatments in this area. Arthrosi Therapeutics founder and 
&#nlThe post FDA grants Fast Track Designation to Arthrosi Therapeuticsâ€™s AR882 for gout treatment appeared first on Pharmaceutical Business review.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(109) "https://www.pharmaceutical-business-review.com/news/fda-fast-track-designation-arthrosi-ar882-gout-treatment/"
  ["blog_url"]=>
  string(109) "https://www.pharmaceutical-business-review.com/news/fda-fast-track-designation-arthrosi-ar882-gout-treatment/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:24"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA grants Fast Track Designation to Arthrosi Therapeuticsâ€™s AR882 for gout treatme

This designation is a critical step in accelerating the drug’s development and review process, recognising the

array(40) {
  [0]=>
  string(4) "9375"
  ["article_id"]=>
  string(4) "9375"
  [1]=>
  string(83) "EMA validates Type II Variation application for ENHERTU for breast cancer treatment"
  ["article_title"]=>
  string(83) "EMA validates Type II Variation application for ENHERTU for breast cancer treatment"
  [2]=>
  string(150) "ENHERTU, a HER2 directed a DXd antibody drug conjugate (ADC), was discovered by Daiichi Sankyo and is being jointly developed and commercialised by Da"
  ["short_description"]=>
  string(150) "ENHERTU, a HER2 directed a DXd antibody drug conjugate (ADC), was discovered by Daiichi Sankyo and is being jointly developed and commercialised by Da"
  [3]=>
  string(575) "ENHERTU, a HER2 directed a DXd antibody drug conjugate (ADC), was discovered by Daiichi Sankyo and is being jointly developed and commercialised by Daiichi Sankyo with AstraZeneca. The 
&#nlThe post EMA validates Type II Variation application for ENHERTU for breast cancer treatment appeared first on Pharmaceutical Business review.&#nl"
  ["description"]=>
  string(575) "ENHERTU, a HER2 directed a DXd antibody drug conjugate (ADC), was discovered by Daiichi Sankyo and is being jointly developed and commercialised by Daiichi Sankyo with AstraZeneca. The 
&#nlThe post EMA validates Type II Variation application for ENHERTU for breast cancer treatment appeared first on Pharmaceutical Business review.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(88) "https://www.pharmaceutical-business-review.com/news/ema-enhertu-breast-cancer-treatment/"
  ["blog_url"]=>
  string(88) "https://www.pharmaceutical-business-review.com/news/ema-enhertu-breast-cancer-treatment/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:24"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

EMA validates Type II Variation application for ENHERTU for breast cancer treatment

ENHERTU, a HER2 directed a DXd antibody drug conjugate (ADC), was discovered by Daiichi Sankyo and is being jointly d

array(40) {
  [0]=>
  string(4) "9376"
  ["article_id"]=>
  string(4) "9376"
  [1]=>
  string(70) "Aarvik announces ADC option exercise by collaboration partner ArriVent"
  ["article_title"]=>
  string(70) "Aarvik announces ADC option exercise by collaboration partner ArriVent"
  [2]=>
  string(150) "This move comes as part of the research collaboration agreement initiated on 21 December 2021. As per the 2021 deal, Aarvik carried out the discovery "
  ["short_description"]=>
  string(150) "This move comes as part of the research collaboration agreement initiated on 21 December 2021. As per the 2021 deal, Aarvik carried out the discovery "
  [3]=>
  string(546) "This move comes as part of the research collaboration agreement initiated on 21 December 2021. As per the 2021 deal, Aarvik carried out the discovery and preclinical development 
&#nlThe post Aarvik announces ADC option exercise by collaboration partner ArriVent appeared first on Pharmaceutical Business review.&#nl"
  ["description"]=>
  string(546) "This move comes as part of the research collaboration agreement initiated on 21 December 2021. As per the 2021 deal, Aarvik carried out the discovery and preclinical development 
&#nlThe post Aarvik announces ADC option exercise by collaboration partner ArriVent appeared first on Pharmaceutical Business review.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(79) "https://www.pharmaceutical-business-review.com/news/aarvik-adc-option-arrivent/"
  ["blog_url"]=>
  string(79) "https://www.pharmaceutical-business-review.com/news/aarvik-adc-option-arrivent/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:24"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Aarvik announces ADC option exercise by collaboration partner ArriVent

This move comes as part of the research collaboration agreement initiated on 21 December 2021. As per the 2021 deal,

array(40) {
  [0]=>
  string(4) "9377"
  ["article_id"]=>
  string(4) "9377"
  [1]=>
  string(79) "FDA grants priority review for Bavarian Nordicâ€™s chikungunya vaccine BLA"
  ["article_title"]=>
  string(79) "FDA grants priority review for Bavarian Nordicâ€™s chikungunya vaccine BLA"
  [2]=>
  string(150) "The vaccine candidate is a virus-like particle (VLP)-based, adjuvanted vaccine designed for active immunisation against chikungunya virus (CHIKV) infe"
  ["short_description"]=>
  string(150) "The vaccine candidate is a virus-like particle (VLP)-based, adjuvanted vaccine designed for active immunisation against chikungunya virus (CHIKV) infe"
  [3]=>
  string(602) "The vaccine candidate is a virus-like particle (VLP)-based, adjuvanted vaccine designed for active immunisation against chikungunya virus (CHIKV) infection. This expedited review process is a significant step towards 
&#nlThe post FDA grants priority review for Bavarian Nordic’s chikungunya vaccine BLA appeared first on Pharmaceutical Business review.&#nl"
  ["description"]=>
  string(602) "The vaccine candidate is a virus-like particle (VLP)-based, adjuvanted vaccine designed for active immunisation against chikungunya virus (CHIKV) infection. This expedited review process is a significant step towards 
&#nlThe post FDA grants priority review for Bavarian Nordic’s chikungunya vaccine BLA appeared first on Pharmaceutical Business review.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(88) "https://www.pharmaceutical-business-review.com/news/bavarian-nordic-chikungunya-vaccine/"
  ["blog_url"]=>
  string(88) "https://www.pharmaceutical-business-review.com/news/bavarian-nordic-chikungunya-vaccine/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:24"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA grants priority review for Bavarian Nordicâ€™s chikungunya vaccine BLA

The vaccine candidate is a virus-like particle (VLP)-based, adjuvanted vaccine designed for active immunisation again

array(40) {
  [0]=>
  string(4) "9378"
  ["article_id"]=>
  string(4) "9378"
  [1]=>
  string(69) "Persist AI and Nivagen to develop AI-driven LAI manufacturing process"
  ["article_title"]=>
  string(69) "Persist AI and Nivagen to develop AI-driven LAI manufacturing process"
  [2]=>
  string(150) "The collaboration between Persist AI and Nivagen will leverage AI-based formulation technology of Persist alongside Nivagen’s manufacturing prow"
  ["short_description"]=>
  string(150) "The collaboration between Persist AI and Nivagen will leverage AI-based formulation technology of Persist alongside Nivagen’s manufacturing prow"
  [3]=>
  string(592) "The collaboration between Persist AI and Nivagen will leverage AI-based formulation technology of Persist alongside Nivagen’s manufacturing prowess. The goal is to streamline and expedite the development and 
&#nlThe post Persist AI and Nivagen to develop AI-driven LAI manufacturing process appeared first on Pharmaceutical Business review.&#nl"
  ["description"]=>
  string(592) "The collaboration between Persist AI and Nivagen will leverage AI-based formulation technology of Persist alongside Nivagen’s manufacturing prowess. The goal is to streamline and expedite the development and 
&#nlThe post Persist AI and Nivagen to develop AI-driven LAI manufacturing process appeared first on Pharmaceutical Business review.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(90) "https://www.pharmaceutical-business-review.com/news/persist-nivagen-manufacturing-process/"
  ["blog_url"]=>
  string(90) "https://www.pharmaceutical-business-review.com/news/persist-nivagen-manufacturing-process/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:24"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Persist AI and Nivagen to develop AI-driven LAI manufacturing process

The collaboration between Persist AI and Nivagen will leverage AI-based formulation technology of Persist alongside N

array(40) {
  [0]=>
  string(4) "9379"
  ["article_id"]=>
  string(4) "9379"
  [1]=>
  string(63) "Sandozâ€™s Enzeevu secures FDA approval for nAMD treatment"
  ["article_title"]=>
  string(63) "Sandozâ€™s Enzeevu secures FDA approval for nAMD treatment"
  [2]=>
  string(150) "Enzeevu is designed to improve and maintain visual acuity in patients suffering from nAMD, a condition that is a primary cause of vision impairment am"
  ["short_description"]=>
  string(150) "Enzeevu is designed to improve and maintain visual acuity in patients suffering from nAMD, a condition that is a primary cause of vision impairment am"
  [3]=>
  string(536) "Enzeevu is designed to improve and maintain visual acuity in patients suffering from nAMD, a condition that is a primary cause of vision impairment among individuals over 50 
&#nlThe post Sandozâ€™s Enzeevu secures FDA approval for nAMD treatment appeared first on Pharmaceutical Business review.&#nl"
  ["description"]=>
  string(536) "Enzeevu is designed to improve and maintain visual acuity in patients suffering from nAMD, a condition that is a primary cause of vision impairment among individuals over 50 
&#nlThe post Sandozâ€™s Enzeevu secures FDA approval for nAMD treatment appeared first on Pharmaceutical Business review.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/sandoz-enzeevu-fda-approval/"
  ["blog_url"]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/sandoz-enzeevu-fda-approval/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:24"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Sandozâ€™s Enzeevu secures FDA approval for nAMD treatment

Enzeevu is designed to improve and maintain visual acuity in patients suffering from nAMD, a condition that is a prim

Showing 7945 to 7956 of 664
First
Previous
1
2
..
660
661
662
663
664
Next
Last

How personal loss and hope drove Elaine Maynardâ€™s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimerâ€™s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

Commentary: Will you hire and retain persons with mental health conditions?

Coronavirus: What Your Healthcare HR Department Needs to Know Right Now

Coronavirus: Social distancing gap should be greatly increased, MIT researcher says

Infected but Feeling Fine: The Unwitting Coronavirus Spreaders

6 Times You Should Talk to Human Resources

Singapore PM warns that healthcare spending is rising faster than GDP

AI’s Growing Role in Human Resources

Fostering Organizational Collaboration in the Life Sciences

Pressure Monitoring Devices Market Development and Forecast Report 2019| Philips Healthcare, GE Healthcare, Medtronic

Here's How to Offer Competitive Benefits Without Sacrificing Salary

The New Rules of Personal Branding For Job Seekers